Information and Results. Except as otherwise provided in this Agreement, the Parties will make available and disclose to one another Development Data and other results of work conducted prior to and in preparation for the JSC meetings, by the deadline and in the level of detail, form and format to be designated by the JSC; provided, however, that, in any event, each Party shall to the extent reasonably possible provide the other Party with monthly updates regarding its activities hereunder, preferably [*****] prior to each JSC meeting.
Information and Results. Except as otherwise provided, the Parties will make available and disclose to one another all results of the work conducted pursuant to the Research Program prior to and in preparation for Research Management Committee meetings, in the form and format to be designated by the Research Management Committee.
Information and Results. Except as otherwise provided in this Agreement, the Parties will make available and disclose to one another preclinical Development Data and other results of work conducted pursuant to each Program prior to and in preparation for the JRC meetings, by the deadline and in the level of detail, form and format to be designated by the JRC; provided, however, that, in any event, each Party shall to the extent reasonably possible provide the other Party with quarterly updates regarding its work pursuant to the Programs preferably [*****] prior to each JRC meeting.
Information and Results. Except as otherwise provided in this Agreement, the Parties will make available and disclose to one another all material Results generated pursuant to the Target Discovery Program, a Target Validation Program or a Compound Discovery Program prior to and in preparation for the JSC or applicable subcommittee meetings, by the deadline and in the form and format to be designated by the JSC or applicable subcommittee.
Information and Results. Except as otherwise provided, the Parties will make available and disclose to one another all results of the work conducted pursuant to the Development Program prior to and in preparation for the Development Committee meetings, by the deadline and in the form and format to be designated by the Development Committee. [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Information and Results. Except as otherwise provided, the Parties will make available and disclose to one another all results of the work conducted pursuant to the Design & Development Program prior to and in preparation for the Steering Committee meetings, by the deadline and in the form and format to be designated by the Steering Committee. The Parties also will identify the critical events which must be reported between the firms, and establish reporting processes and responsibilities prior to first Product launch. Ambrx Inc. / Elanco Animal Health Collaborative Research, License & Commercialization Agreement (continued) CONFIDENTIAL
Information and Results. Except as otherwise provided, the Parties will make available and disclose to one another all results of the work conducted pursuant to the Collaboration prior to and in preparation for the Steering Committee meetings, by the deadline and in the form and format to be designated by the Steering Committee.
Information and Results. Except as otherwise provided in this Agreement, the Parties will make available and disclose to one another [***] prior to and in preparation for the JRC, JPT or applicable subcommittee meetings, [***] to be designated by the JRC, JPT or applicable subcommittee; provided, that (a) [***] and (b) [***].
Information and Results. Except as otherwise provided, the Parties will make available and disclose the Progress Reports prior to and in preparation for Research Committee meetings, in the form and format to be designated by the Research Committee.
Information and Results. Except as otherwise agreed by FemPharm in writing, Vivus shall make available and disclose to FemPharm, no less often than once every six (6) months, in the form selected by Vivus and reasonably acceptable to Vivus, and to the extent not previously disclosed, all patient results from Clinical Trials by Vivus or its Affiliate on Products under this Agreement and all Regulatory Materials prepared by Vivus or its Affiliate, including any NDA filed by Vivus or its Affiliate with the FDA for a Product under this Agreement. It is understood that inadvertent failure to disclose any of the foregoing information will not be deemed a breach, provided that Vivus makes the disclosure of such information promptly after becoming aware that such information has not been disclosed. To the extent Vivus has the right to provide such patient results from the Clinical Trials by its sublicensees on Products under this Agreement, Vivus will also make such results available in the manner described above. Vivus agrees to use good faith, diligent efforts to obtain such rights from its sublicensee. If the NDA is filed by a sublicensee Vivus, Vivus will use good faith, diligent efforts to obtain the right to disclose the NDA to FemPharm. As between Vivus and FemPharm, each Party will own all results and data that it generates, subject to any licenses granted under this Agreement to the other Party. In particular, as between Vivus and FemPharm, Vivus will own all clinical data and results of testing Product generated by Vivus under this Agreement (the "Data"). FemPharm and its Affiliates have the right to use all Data required to be delivered by Vivus solely in developing and seeking regulatory approval of a Product in the Field in Australia and New Zealand, and no Data, Regulatory Materials, or other Know-How provided by Vivus shall be used for any other purpose, such as without limitation for purposes of development or marketing approval for a country other than New Zealand and Australia, except as otherwise agreed by the Parties in a separate writing. Such Know-How will be disclosed to licensees of FemPharm and the Acrux Controlled Affiliates for Australia or New Zealand only to the extent the licensee provides equivalent disclosure to Vivus and Vivus' sublicensees.
